MiniMed Group has delivered a sharp reversal from the cautious pre-earnings setup documented in recent notes: the stock has rallied 18.5% on the week and the Street has moved in unison to lift targets, even as short sellers — who spent August covering — have now started rebuilding positions.
The analyst reaction is the defining story of this week. Seven firms raised price targets on September 1-2, all while maintaining positive ratings. BofA Securities lifted to $28 from $24, UBS moved to $28 from $25, and Evercore ISI made the most aggressive jump — to $27 from $20. Wells Fargo, Mizuho, Citigroup, and BTIG all raised in the same session. Not a single firm downgraded or trimmed. The mean consensus target now sits at $24.42, already close to the current $22.42 price, but several individual targets at $27-28 suggest the Street sees further room from here. Bulls point to MiniMed's strengthened position in the diabetes management market and a pipeline of new products; bears flag regulatory approval timelines and rising competition from better-capitalised international players. The consensus skew after this batch of raises is firmly constructive.
The positioning picture has flipped relative to what previous notes described. Through August, the dominant story was short-covering into earnings alongside defensive options positioning — a setup that paid off once the stock gapped higher. Now the dynamic has reversed. Short interest jumped 13% on the day of earnings to 7.93 million shares, up 15% on the week. That is a material rebuild, and the ORTEX short score has followed, climbing to 77.8 — its highest reading in the tracked history — having moved up from 75.4 a week ago. Shorts who covered into the print are not necessarily back; this looks more like fresh positioning by bears who view the post-earnings rally as an overshoot.
The borrow market has tightened accordingly. Availability now sits at roughly 19%, meaning only one share remains available for every five already lent out. Cost to borrow has climbed to 7.1% — up 61% on the week and nearly six times the mid-August level when it briefly dipped below 1%. That is a meaningful shift in the friction cost for shorts, but at 7.1% it is still far from prohibitive. The one signal pointing the other way is options: the put/call ratio has actually fallen back to 1.68, below the 20-day mean of 2.01, which suggests options traders are less defensive now than they were heading into the print. The sharp narrowing from the 2.79 reading seen just before earnings marks a notable rotation away from downside hedging.
Ownership context adds an important backdrop. Medtronic plc holds 90% of MMED shares via a Schedule 13G passive filing — the company was spun out relatively recently, and the institutional register beyond Medtronic remains thin, with MFS, Millennium, and Citadel each holding around 1% or less. That concentrated ownership structure limits the free float and partly explains why availability has been so volatile: there are simply fewer shares in the lending pool to absorb surges in short demand. Insider activity is minimal and mechanical — the only recent Form 4 filings are tax-withholding transactions by the CEO and Chief Product Officer in July, not discretionary trades.
The next scheduled event is the Q3 earnings release on October 9. Between now and then, the key tension is whether the short rebuild at 7.93 million shares — coming at higher borrow cost into a tight lending pool — reflects genuine fundamental scepticism about the post-spin trajectory, or simply opportunistic fading of a one-day pop that the Street's price-target cluster at $26-28 would argue is not yet fully priced in.
See the live data behind this article on ORTEX.
Open MMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
